Capsule-in-Capsule Technology - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Capsule-in-Capsule Technology
The author outlines how to choose carriers and capsule shells according to dosage requirements and intended use. This article is part of a special Drug Delivery issue.

Pharmaceutical Technology
pp. s26-s29


The author prepared a capsule-in-capsule system for investigation. Model compounds caffeine (Sigma Aldrich, St. Louis, MO) and nicotinamide (Sigma Aldrich) were chosen. PEG 6000 Ph. Eur. (BASF, Ludwigshafen, Germany), Gelucire 50/13 (Gattefossé, St-Priest France), and Labrafil (Gattefossé) were used as thermosoftening carriers.


Figure 4: Dissolution profiles for series 3 doses. The outer Labrafil (Gattefossé, St-Priest, France) capsule contained caffeine (caff.), and the inner Gelucire 50/13 (Gattefossé) capsule contained nicotinamide (nic.). Results after 0, 2, 3, and 5 months' storage are shown. (FIGURE IS COURTESY OF THE AUTHOR)
Trial formulations of model compounds caffeine and nicotinamide were prepared at bench-scale in the selected thermosoftening carriers, which are suited to liquid-filled hard capsules. Inner clear/clear size 2 gelatin capsules (Capsugel, Peapack, NJ) were filled manually at 300 mg to provide 5 mg of nicotinamide in PEG 6000 or in Gelucire 50/13. Filled capsules were banded with gelatine. A proportion of nicotinamide–PEG 6000 capsules was enteric-coated with Eudragit L100-55 (Röhm, Darmstadt, Germany) at 10 mg/cm2 using a Strea-1 coater (GEA Pharma Systems, Wommelgem, Belgium). These inner size 2 capsules, with or without enteric coat, were placed into size 0 capsules.

The second formulation was also filled into the size 0 capsules at the required fill weight to provide 5 mg of caffeine in, Labrafil and the capsules were sealed. Samples comprising nicotinamide–PEG 6000 and caffeine–Labrafil, nicotinamide–PEG 6000 enteric coated and caffeine–Labrafil, and nicotinamide–Gelucire 50/13 and caffeine–Labrafil were designated as series 1, 2, and 3, respectively.

Dissolution testing was carried out in European Pharmacopoeia Apparatus 2 (i.e., paddles), using 900 mL of dissolution medium, stirring at 100 rpm. Dissolution testing of series 1 and 3 samples used water as the dissolution medium. Testing of series 2 samples used 0.1N HCl for 2 h, followed by adjustment to pH 7.0 using NaOH. Release of each component was determined by high-performance liquid chromatography at 262 nm. Capsule integrity and dissolution profiles were monitored at time zero and after two, three, and five months' storage at 25 °C in glass bottles.

Figures 2, 3, and 4 show in vitro dissolution profiles for all series at 0, two, three, and five months. Series 1 represented a nominal fast–fast release profile. Series 2 represented a fast–enteric-coated–fast release profile. Series 3 represented a fast–slow release profile. The formulations were designed to represent differing formats using widely-accepted thermosoftening carriers. Here, PEG 6000 and Labrafil provided matrices considered suitable for fast release of each model compound. Gelucire 50/13 provided a matrix considered suitable for the slow release of nicotinamide. The three sample series demonstrated that differing in vitro release profiles could be achieved readily using the approach described here

It is important that the system show the potential for product stability, particularly in terms of consistent integrity of the double-capsule format and the required release profiles. Each sample series demonstrated continuing capsule integrity and dissolution stability over the five-month time period. This result was particularly important to the sample in which the inner capsule was enteric-coated because the formulation contained in the outer capsule could adversely affect the enteric coat of a coated inner capsule. In this example, Labrafil was compatible with the enteric coat. It is worth noting that another common liquid-fill carrier (i.e., Labrasol, Gattefosse) was incompatible with the coating agent used in this study.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here